

# Veerle Mh CoupÃ©

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10822165/publications.pdf>

Version: 2024-02-01

40  
papers

995  
citations

430874

18  
h-index

434195

31  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study. <i>Journal of Medical Screening</i> , 2022, 29, 72-83.	2.3	8
2	Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. <i>Medical Decision Making</i> , 2022, 42, 956-968.	2.4	4
3	Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands. <i>JCO Precision Oncology</i> , 2022, , .	3.0	10
4	The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1831-1846.	2.4	6
5	Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening. <i>Value in Health</i> , 2021, 24, 206-215.	0.3	4
6	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	2.5	0
7	Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening. <i>Annals of Internal Medicine</i> , 2021, 174, 1224-1231.	3.9	16
8	Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. <i>International Journal of Cancer</i> , 2020, 146, 2968-2978.	5.1	8
9	The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. <i>Medical Journal of Australia</i> , 2020, 212, 72-81.	1.7	22
10	Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression. <i>Journal of Pathology</i> , 2020, 250, 288-298.	4.5	33
11	Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 563-571.	1.4	0
12	Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study. <i>Lung Cancer</i> , 2020, 141, 89-96.	2.0	15
13	Patient-reported Outcomes After the Treatment of Early Stage Non-small-cell Lung Cancer With Stereotactic Body Radiotherapy Compared With Surgery. <i>Clinical Lung Cancer</i> , 2019, 20, 370-377.e3.	2.6	10
14	Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 1772-1779.	2.3	10
15	Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. <i>International Journal of Cancer</i> , 2018, 143, 269-282.	5.1	28
16	Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 689-698.	1.1	23
17	Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1450-1461.	2.5	26
18	MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer. <i>Oncotarget</i> , 2018, 9, 29445-29452.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Splenic volume differentiates complicated and non-complicated celiac disease. United European Gastroenterology Journal, 2017, 5, 374-379.	3.8	12
20	Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy. Annals of Internal Medicine, 2017, 167, 544.	3.9	52
21	MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER. International Journal of Technology Assessment in Health Care, 2017, 33, 681-690.	0.5	3
22	Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using <sup>18</sup> F-FDG-PET-CT and/or diffusion-weighted MRI. BMC Cancer, 2017, 17, 256.	2.6	9
23	Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 167, 855.	3.9	39
24	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
25	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. RMD Open, 2017, 3, e000502.	3.8	3
26	Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis. Ecanermedicalscience, 2016, 10, 684.	1.1	20
27	Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality—Model-Based Exploration of the Serrated Pathway. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 135-144.	2.5	25
28	Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?. BMC Gastroenterology, 2014, 14, 217.	2.0	19
29	Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointestinal Endoscopy, 2012, 76, 136-143.	1.0	24
30	Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. International Journal of Cancer, 2012, 130, 602-610.	5.1	179
31	Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer, 2011, 11, 434.	2.6	19
32	The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine, 2011, 29, 8929-8936.	3.8	25
33	Higher Fecal Immunochemical Test Cutoff Levels: Lower Positivity Rates but Still Acceptable Detection Rates for Early-Stage Colorectal Cancers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 272-280.	2.5	49
34	HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. International Journal of Cancer, 2009, 124, 970-978.	5.1	39
35	How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine, 2009, 27, 5111-5119.	3.8	18
36	Human Papillomavirus Testing Improves Follow-Up after Treatment for Cervical Intraepithelial Neoplasia. Women's Health, 2008, 4, 103-105.	1.5	0

#	ARTICLE	IF	CITATIONS
37	HPV16 and increased risk of recurrence after treatment for CIN. Gynecologic Oncology, 2007, 104, 273-275.	1.4	62
38	Sensitivity Analysis of Probabilistic Networks. Studies in Fuzziness and Soft Computing, 2007, , 103-124.	0.8	31
39	Properties of Sensitivity Analysis of Bayesian Belief Networks. Annals of Mathematics and Artificial Intelligence, 2002, 36, 323-356.	1.3	91
40	Using sensitivity analysis for efficient quantification of a belief network. Artificial Intelligence in Medicine, 1999, 17, 223-247.	6.5	25